Clinical assessment of a novel recombinant simian adenovirus ChAdOx1 as a vectored vaccine expressing conserved Influenza A antigens.

Mol Ther · 2014 · PMC3944330 · PMID 24374965

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a nonsignificant trendno p-value reported

At D21 post-ChAdOx1 NP+M1 vaccination, there was a nonsignificant trend toward higher responses in vaccinees who received the highest dose (5 × 10 10 vp) of ChAdOx1 NP+M1 (1,197 SFUs/10 6 PBMCs), when compared with the lowest dose group (5 × 10 8 vp; 298.3 SFUs/10 6 PBMCs).

also in 5,406 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.